HUE049806T2 - Modified host cells and uses thereof - Google Patents

Modified host cells and uses thereof

Info

Publication number
HUE049806T2
HUE049806T2 HUE14784210A HUE14784210A HUE049806T2 HU E049806 T2 HUE049806 T2 HU E049806T2 HU E14784210 A HUE14784210 A HU E14784210A HU E14784210 A HUE14784210 A HU E14784210A HU E049806 T2 HUE049806 T2 HU E049806T2
Authority
HU
Hungary
Prior art keywords
host cells
modified host
modified
cells
host
Prior art date
Application number
HUE14784210A
Other languages
Hungarian (hu)
Inventor
Michael Kowarik
Stefan J Kemmler
Julien L Quebatte
Christiane Marie-Paule Simone Jeanne Feron
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE049806T2 publication Critical patent/HUE049806T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HUE14784210A 2014-04-17 2014-10-13 Modified host cells and uses thereof HUE049806T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461980988P 2014-04-17 2014-04-17

Publications (1)

Publication Number Publication Date
HUE049806T2 true HUE049806T2 (en) 2020-10-28

Family

ID=51726491

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14784210A HUE049806T2 (en) 2014-04-17 2014-10-13 Modified host cells and uses thereof

Country Status (17)

Country Link
US (1) US20170035900A1 (en)
EP (2) EP3711776B1 (en)
JP (2) JP6682451B2 (en)
CN (1) CN106794237B (en)
BR (1) BR112016023688B1 (en)
CA (1) CA2945542C (en)
CY (1) CY1123403T1 (en)
DK (1) DK3131577T3 (en)
ES (2) ES2939470T3 (en)
HR (1) HRP20201021T1 (en)
HU (1) HUE049806T2 (en)
LT (1) LT3131577T (en)
MX (1) MX2016013631A (en)
PL (1) PL3131577T3 (en)
PT (1) PT3131577T (en)
SI (1) SI3131577T1 (en)
WO (1) WO2015158403A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CN105732818B (en) * 2016-03-02 2019-06-07 中国人民解放军第三军医大学 A kind of pseudomonas aeruginosa recombinant protein POP and its preparation method and application
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
KR20200088342A (en) 2017-10-25 2020-07-22 피벗 바이오, 인크. Methods and compositions for improving genetically engineered microorganisms that fix nitrogen
WO2020006246A1 (en) * 2018-06-27 2020-01-02 Pivot Bio, Inc. Guided microbial remodeling, a platform for the rational improvement of microbial species for agriculture
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
WO2021180532A1 (en) * 2020-03-12 2021-09-16 Malcisbo Ag Vaccines comprising glycoengineered bacteria
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR20090110951A (en) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 System and method for the production of recombinant glycosylated protein in a prokaryotic host
CA2607595C (en) * 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
ES2388556T3 (en) 2006-03-23 2012-10-16 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
SG10201400320TA (en) * 2008-02-20 2014-05-29 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HUE038456T2 (en) * 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
HUE037956T2 (en) * 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Capsular gram-positive bacteria bioconjugate vaccines
CA2847621A1 (en) * 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
KR20150054800A (en) * 2012-09-10 2015-05-20 글리코박신 아게 Bioconjugates comprising modified antigens and uses thereof
ES2905107T3 (en) * 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Host cell modification procedures
CA3125293A1 (en) * 2012-11-07 2014-05-15 Glaxosmithkline Biologicals Sa Production of recombinant vaccine in e. coli by enzymatic conjugation
MX371513B (en) * 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Methods of host cell modification.

Also Published As

Publication number Publication date
BR112016023688A2 (en) 2018-01-30
EP3711776B1 (en) 2023-01-11
LT3131577T (en) 2020-07-27
PL3131577T3 (en) 2020-10-19
ES2805000T3 (en) 2021-02-10
JP2017513480A (en) 2017-06-01
CA2945542C (en) 2024-03-05
CN106794237A (en) 2017-05-31
CA2945542A1 (en) 2015-10-22
ES2939470T3 (en) 2023-04-24
CY1123403T1 (en) 2022-03-24
EP3131577B1 (en) 2020-04-22
PT3131577T (en) 2020-07-17
HRP20201021T1 (en) 2020-10-16
EP3131577A1 (en) 2017-02-22
CN106794237B (en) 2022-04-12
MX2016013631A (en) 2017-02-28
BR112016023688B1 (en) 2024-01-09
WO2015158403A1 (en) 2015-10-22
JP2020114232A (en) 2020-07-30
JP6682451B2 (en) 2020-04-15
SI3131577T1 (en) 2020-08-31
DK3131577T3 (en) 2020-07-13
US20170035900A1 (en) 2017-02-09
EP3711776A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
HK1243332A1 (en) Altering gene expression in modified t cells and uses thereof
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
IL247344B (en) Novel polysaccharide and uses thereof
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL246755A0 (en) Heteroaryls and uses thereof
SG11201609118RA (en) Modified natural killer cells and uses thereof
PL3152226T3 (en) Modified cyclopentapeptides and uses thereof
HK1231555A1 (en) Biomarker and uses thereof
LT3131577T (en) Modified host cells and uses thereof
SG11201704473WA (en) New methods and uses
SG11201610514SA (en) Bioreactor and uses thereof
GB201408091D0 (en) Methods and uses
GB201622225D0 (en) Modified host cells and uses thereof
GB201419897D0 (en) Host cell
PL3229772T3 (en) 6-aryl-9-glycosylpurines and use thereof
EP3233107A4 (en) Nbp158 and uses thereof
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses
AU2014901389A0 (en) Immune cell markers and uses thereof
AU2014901390A0 (en) Immune cell markers and uses thereof
AU2014901388A0 (en) Immune cell markers and uses thereof
GB201415379D0 (en) Gamma T cells and uses thereof
GB201407419D0 (en) Conductive materials and uses thereof
GB201412175D0 (en) Gamma T cells and uses thereof